PT - JOURNAL ARTICLE ED - , TI - Alectinib Approved for ALK+ Lung Cancer AID - 10.1158/2159-8290.CD-NB2016-001 DP - 2016 Feb 01 TA - Cancer Discovery PG - 115--115 VI - 6 IP - 2 4099 - http://cancerdiscovery.aacrjournals.org/content/6/2/115.1.short 4100 - http://cancerdiscovery.aacrjournals.org/content/6/2/115.1.full SO - Cancer Discov2016 Feb 01; 6 AB - The FDA has approved a third ALK inhibitor, alectinib, for advanced ALK-positive non–small cell lung cancer. Two phase II studies show that patients who have become resistant to crizotinib respond well to alectinib; the drug is also effective against brain metastases, which are common in this disease subtype.